<DOC>
	<DOC>NCT00628212</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety and to determine the appropriate dose for phase 3 confirmatory trial, of MP-513 (Teneligliptin) in patients with type 2 Diabetes based on the change of HbA1c and adverse events after 12 weeks administration once daily in multi-center, randomized, double-blind, placebo-controlled, parallel assignment manner.</brief_summary>
	<brief_title>Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Patients who are 20 75 years old Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug Patients whose HbA1c is 6.5 9.5% Patients who were not administered drugs prohibited for concomitant use within 12 weeks before administration of investigational drug. Patients with type 1 diabetes, diabetes mellitus caused by pancreas failure, or secondary diabetes (Cushing disease, acromegaly, etc) Patients with Class III/IV heart failure symptoms according to New York Heart Association (NYHA) functional classification Patients with serious diabetic complications Patients who are habitual excessive alcohol consumption. Patients with severe hepatic disorder or severe renal disorder. Pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>insulin resistance</keyword>
</DOC>